Dr. Abou-Alfa on the Role of Immunotherapy in HCC

Ghassan K. Abou-Alfa, MD
Published: Friday, May 05, 2017



Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with hepatocellular carcinoma (HCC).

The role of immunotherapy could be extending beyond systemic disease because there is interest in combining it with local therapy, explains Abou-Alfa.

There are preliminary data focused on a combination of local therapy and an immunotherapy regimen, which demonstrates a potential success, states Abou-Alfa.
 


Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with hepatocellular carcinoma (HCC).

The role of immunotherapy could be extending beyond systemic disease because there is interest in combining it with local therapy, explains Abou-Alfa.

There are preliminary data focused on a combination of local therapy and an immunotherapy regimen, which demonstrates a potential success, states Abou-Alfa.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x